Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 399-404 , May 2007

Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution

  • Ning Liu

      Affiliations

    • Department of Radiology/Nuclear Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • Current address: Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
    • ,
  • Hongliu Ding

      Affiliations

    • Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • ,
  • Jean-Luc Vanderheyden

      Affiliations

    • Department of Radiology/Nuclear Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • Current address: GE Healthcare, Waukesha, WI, USA.
    • ,
  • Zhihong Zhu

      Affiliations

    • Department of Radiology/Nuclear Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • Current address: Siemens Biomarker Solutions, North Wales, PA, USA.
    • ,
  • Yumin Zhang

      Affiliations

    • Department of Radiology/Nuclear Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    • Corresponding Author InformationCorresponding author. Department of Experimental Imaging, Integrative Pharmacology–Advanced Technology, Abbott Laboratories, Abbott Park, IL 60064, USA. Tel.: +1 847 937 8523; fax: +1 847 938 0072.

Received 23 January 2007 ,Revised 1 February 2007 ,Accepted 15 February 2007.

References 

  1. Kennerdell JR, Carthew RW. Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell. 1998;95:1017–1026
  2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498
  3. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15:188–200
  4. Novina C, Sharp P. The RNAi revolution. Nature. 2004;430:161–164
  5. Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002;110:563–574
  6. Carstea ED, Hough S, Wiederholt K, Welch PJ. State-of-the-art modified RNAi compounds for therapeutics. Idrugs. 2005;8:642–647
  7. Grunweller A, Hartmann RK. RNA interference as a gene-specific approach for molecular medicine. Curr Med Chem. 2005;12:3143–3161
  8. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet. 2005;54:117–142
  9. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther. 2005;107:222–239
  10. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett. 2005;579:5996–6007
  11. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34:322–333
  12. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature. 2002;418:38–39
  13. Kraynack BA, Baker BF. Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA. 2006;12:163–176
  14. Zhang YM, Wang Y, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. In vitro investigations of tumor targeting with (99m)Tc-labeled antisense DNA. J Nucl Med. 2001;42:1660–1669
  15. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022–2028
  16. Zhang YM, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. Influences of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of 99mTc attached to antisense DNA. Eur J Nucl Med. 2000;27:1700–1707
  17. Zhang YM, Rusckowski M, Liu N, Liu C, Hnatowich DJ. Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm. 2001;16:411–419
  18. Zhang YM, He J, Liu G, Venderheyden J-L, Gupta S, Rusckowski M, et al. Initial observations of 99mTc-labeled locked nucleic acids for antisense targeting. Nucl Med Commun. 2004;25:1113–1118
  19. Wang Y, Chang F, Zhang Y, Liu N, Liu G, Gupta S, et al. Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjug Chem. 2001;12:807–816
  20. Zhang Y-M, Tung C-H, He J, Liu N, Yanachkov I, Liu G, et al. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Nucl Med Biol. 2006;33:263–269
  21. Mang'ere K, Liu G, Wang Y, Zhang Y, Liu N, Gupta S, et al. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications. Eur J Nucl Med. 2001;28:1682–1689
  22. Edwards DS, Liu S, Ziegler MC, Harris AR, Crocker AC, Hemingway AJ, et al. RP463: a stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging. Bioconjug Chem. 1999;10:884–891
  23. Liu G, Zhang S, He J, Liu N, Gupta S, Rusckowski M, et al. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice. Q J Nucl Med. 2002;46:233–243

PII: S0969-8051(07)00043-1

doi: 10.1016/j.nucmedbio.2007.02.006

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 399-404 , May 2007

Article Tools

* Image Usage & Resolution